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ABSTRACT 
 
Dengue viral infection (DVI) is amongst a big Global health challenges. The clinical manifestations of 
disease ranges from subclinical Dengue fever (DF) to the complicated dengue haemorrhagic fever 
(DHF) and dengue shock syndrome (DSS). Reason behind this is the absence of specific tetravalent 
vaccine and the anti virals. The mortality rate with the infection might exceed upto 5%. Therefore, 
there is a dire need to emphasize the adoption of preventive strategies and to control the vector 
Aedesaegypti mosquito population. Moreover, the regular cross sectional, age stratified, serological 
surveys are the surveillance tools for monitoring the impact of Dengue prevention/ control and a 
better way to plan for potential epidemics. 
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INTRODUCTION  
 
Dengue Fever ‘ABreak Bone Fever’   
A Spanish word ‘dengue’ means Fastidious or 
Careful.  An  American  physician  Benjaman 
Rush  first  gave  Dengue  fever  a  name  Break 
Bone  fever  or  Bone  Crush  Disease.  This  is 
attributed to the major complications of disease 
i.e.  myalgias  and  arthralgias  (Harper,  2008; 
Reed, 2008). According to the WHO report it is 
amongst the most common causes of arboviral 
diseases  worldwide  (Rathor,  1998;  Heyman, 
2008). Aedes aegypti is the principle vector in 
the  transmission  of  disease.  This  special 
mosquito is well adapted to humans and prefers 
to live in clean surroundings in close proximity 
to clean human surroundings (Heyman, 2008). 
 
Dengue Virus and Serotypes  
It  is  the  most  common  cause  of  arboviral 
diseases  worldwide  (Yasmashiro,  2004).  It 
consists  of  four  serotypes.  DEN  1,  DEN  2, 
DEN  3  and  DEN  4.These  serotypes  were 
classified  by  Albert  Sabin  in  1944.  Infection 
with  DEN  viral  serotypes  has  been  a  major 
concern in DEN endemic areas worldwide. The 
reason behind this is the co circulation of all the 
four serotypes (Heyman, 2008; Gubler, 1998). 
  
Pathogenesis 
These  serotypes  are  responsible  for  the 
production  of  serotype  specific  IgG  antibody 
mediated  protective  immunity  following  the 
first  infection  (Gubler,  1996).  There  are  two 
types of serological responses in Dengue viral 
infected patients i.e. primary and the secondary 
ones.  The  response  is  dependent  upon  the 
immunological status of the infected individual. 
A primary response is seen in those who are not 
immune  to  flaviviruses,  while  a  secondary 
response  is  seen  in  those  who  had  previous 
flaviviral  infection.  It  will  be  responsible  for 
the pathogenesis of DF, DHF and DSS. This 
primary  response  can  be  very  well 
differentiated from the secondary response by 
ELISA method for diagnostic purpose (Kumar, 
2005). 
 
Commonest Serotype 
 Previously  DEN  2  serotypes  were  more 
common  but  recent  studies  have  shown  the 
increased  prevalence  of  DEN  1and  DEN  3 
serotypes (Lolekha, 2004; Khan, 2006). 
  
Prevalence  of  DEN  2  And  3  Serotypes  in 
Pakistan 
In  Pakistan  DEN  2  serotypes  predominates 
followed by DEN 3 serotype (US News 2010). 
  
WHO Dengue Report about Pakistan 
The WHO and US centers for disease control 
has  considered  dengue  fever  a  major  health 
threat  for  Brazil,  Pakistan  and  India  (CDC 
Report, 2013). 
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Dengue in Pakistan       
In  1994  first  outbreak  of  DHF  occurred  at 
Karachi,  Pakistan.  In  1995,  second  outbreak 
occurred  in  Baluchistan.  In  2002,  the 
educational  programmes  for  Aedes  aegypti 
mosquitoes were established (Almani, 2008). In 
2003,  10  cases  were  confirmed  along  with  4 
deaths  at  Haripur  (Qasim,  2008).  In 
Rawalpindi,  from  September  to  November 
2008, 49 positive cases detected. Out of which 
23 reported at BBH and 26 at HFH (Edelman, 
2007). 
 
Dengue A Global Health Problem 
The absences of specific vaccine and anti viral 
treatment  of  DF  are  the  main  reasons  for 
making it a global health problem (Hapugoda, 
2007; Gathatry, 2009). 
 
Dengue Vaccine 
It has been very well analyzed from the current 
study that the final winning goal of the fight 
will  be  the  discovery  of  DV  vaccine.  The 
vaccine  must  be  tetravalent  to  provide 
immunity  against  all  4  circulating  serotypes. 
Thus  reducing  the  chances  of  cross  reacting 
antibodies  formation.  Researchers  have 
discovered  dozens  of  areas  on  vector  Aedes 
mosquito  and  about  42  dengue  specific  host 
factors.  These  can  serve  as  targets  for  new 
kinds of drugs and vaccines (Hastlead, 2002). 
Novartis  and  Sanofi  Aventis  are  devoted  to 
produce a long awaited vaccine against DV. It 
will be available by the end 2012 or 2013. This 
vaccine contains proteins from  all the 4 viral 
strains. The vaccine is still under trials and has 
proven effective result against all the 4 strains 
of  DV  when  given  and  tested  on  monkeys. 
(Sanofi  Aventis,  2009;  Serafini,  2007).The 
vaccine design will be a promising strategy to 
prevent Dengue infection (Evans, 2009). 
 
Dengue a Growing Threat 
Dengue viral infection is becoming a growing 
threat  to  the  population  of  developing  world 
(Senanayake,  2006).  DF  is  a  terrible  viral 
disease. It has involved many tropical regions 
of the world. It has been estimated that about 
40% of world population is at the risk for this 
infection (Durand, 2003). 
  
Endemic Viral Disease 
DF  is  an  endemic  viral  disease  affecting  the 
tropical  and  subtropical  regions  around  the 
World,  especially  in  urban  and  semi  urban 
areas. The global prevalence of DF has grown 
dramatically  in  recent  decades.  It  is  now 
endemic  in  more  than  hundred  countries  of 
Africa, America, Eastern Mediterranean, South 
East  Asia  and  the  Western  Pacific  (Focks, 
2000). 
 
Global Epidemiological Pattern of Dengue 
The epidemiology of DF has been drastically 
changed, resulting in the increased incidence of 
disease worldwide along with the worsening of 
clinical symptoms. The course of epidemic is 
dependent upon the rate of contact between the 
host,  the  infecting  vector  and  the  threshold 
theory. This theory states that the introduction 
of few infected individuals in the community 
will  not  give  rise  to  an  outbreak  unless  the 
density of vector exceeds a certain critical level 
(CDC Report, 1980).  
The  incidence  of  DHF  has  dramatically 
increased in South East Asia, South Pacific and 
America  during  the  last  25  years.  The  first 
epidemic  of  DF  was  notified  by  American 
Government  in  1981  at  Cuba.  The  second 
occurred at Venezuela in 1989 - 90 (Srivastava, 
1990).  In  1980,  several  cases  of  DF  were 
identified in Southern Texas. This was found to 
be  associated  with  epidemic  Dengue  in 
adjacent  states  of  Mexico  (Effler,  2005).    In 
1990,  Indian  Government  disclosed  the  first 
epidemic of DF (Noisakran, 2008).The Hawaii 
government  notified  first  DF  epidemic  in 
2001(Ewathorn, 2007). 
 
Mortality Rate from DHF/DSS 
The  death  rates  associated  with  DHF/DSS  is 
approximately  5%  predominantly  in  children 
under 15 years (Clark, 2005). 
   
Dengue Shock Syndrome 
DSS is associated with the high morbidity and 
mortality  rates.  This  is  especially  in  cases  of 
prolonged  shock,  massive  bleeding  and 
hemoconcenteration  more  than  22%.  The 
morbidity and mortality rates can be decreased 
by early diagnosis and prompt management of 
the condition (Siqueira, 2005). 
 
Estimated Financial Losses with DF/DHF   
DF and DHF is a substantial health burden in 
Thailand population. The financial losses were 
observed to be 61 US dollars per family. This is 
more  than  the  average  monthly  income  of 
Thailand population. The results  of  the  study 
indicated  that  dengue  prevention,  control  and Asian J Agri Biol, 2013, 1(1):38-42. 
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research must be given equal importance as that 
of  diseases  currently  given  priority  (Itoda, 
2006). 
  
LITERATURE REVIEW 
 
Predisposing Factors 
The contributing factors in the predisposition of 
disease  includes  the  age  of  patient  (Smith, 
2005), immune status, type of virus infecting, 
humid  climates  especially  rainy  season  and 
temperature  >20
0C.  The  residents  returning 
from  overseas  countries  where  dengue  is 
endemic,  increase  in  population  growth, 
unplanned  urbanization,  increase  in  the 
international trade and increase in air travel. All 
of these provide an ideal way of transporting 
virus to new areas (Hastlead,2002;Smith,2004). 
These  factors  despite  having  vector  control 
programmes and public awareness contributes 
to  the  outbreak  in  several  urbanized  areas 
(Rannos, 2008). Unplanned urbanization is one 
of the important reasons for the persistence of 
infection  in  many  tropical  and  subtropical 
countries  (Nakamura,  2009).  The  discarded 
waste tires and buckets are the favorite sites for 
proliferation  of  Aedes  aegypti  mosquito 
population (Guzman, 2004). 
  
Lab Findings in Primary Infection 
The  initial  lab  diagnosis  of  DF  includes  the 
changes  in  blood  peripheral  film  i.e. 
thrombocytopenia and leucocytopenia.  While 
on  bone  marrow  examination  extreme 
plasmacytosis and haemophagocytosis are also 
seen (Wichman, 2006). 
   
Methods for DV Isolation 
An  appropriate,  rapid  and  easily  accessible 
diagnostic  method  will  be  useful  for 
epidemiological  surveillance,  control,  and 
better management of diseases (Khanna, 2004). 
There are three important approaches for DV 
isolation:    a;  Serological  tests.  b;  Viral 
isolation.  c;  Molecular  tests.  Theserological 
tests include the Haemagglutination Inhibition 
(HI),  Complement  Fixation  test  (CF), 
Neutralization tests (NT), IgM and IgG ELISA 
and  Indirect  Immuno  Fluorescent  Assay 
(IFA).The  Viral  Isolation  includes  the 
inoculation  of  mosquito  cell  culture,  and 
inoculation  of  mammalian  cell  cultures.  The 
Molecular analysis includes the test for nucleic 
acid  hybridization,  RT-  PCR  and  DF  Virus 
RNA detection (Hastlead, 2002). 
 
Serological Diagnosis    
The identification of anti Dengue antibodies is 
the  most  reliable  method  for  diagnosing  DF. 
These  tests  are  cost  effective,  rapid,  easily 
available and accurate for the diagnosis of DF.  
Sensitivity and Specificity Of ELISA: ELISA 
is  considered  to  be  a  highly  sensitive  and 
specific method for the diagnosis of DF. It is 
93.3% specific for DF virus (Kao, 2005). 
 
Strategies for Disease Control/Prevention 
The  disease  control  and  prevention  is  mainly 
focused  on  vector  control  activities  and  the 
surveillance  that  incorporates  country
’s 
participation (Takhaynpuya, 2006). 
  
Pharmaceutical Trials to Discover anti- DV 
Treatment  
Studies  on  ribavirin  and  mycophenolic  acid 
have shown that there is 5 fold increase in the 
defective viral RNA production with each drug 
(Fisher, 2005). 
 
Dengue Prevention and Control 
Excellent  daily  surveillance  and  coordinated 
correspondence  between  administration, 
epidemiologist  and  infection  disease  units 
provide a proactive approach for the prevention 
and control of disease in specific regions of the 
world (Egger, 2008). 
 
Importance of Seroprevalence Studies 
Moreover,  the  regular  cross  sectional,  age 
stratified,  serological  surveys  are  the 
surveillance tools for monitoring the impact of 
Dengue prevention and control.  It also helps to 
plan  for  potential  epidemics.  Most  countries 
throughout  the  world  have  poor  surveillance 
capabilities  for  the  detection  of  both  i.e., 
Dengue  and  the  vector  Aedes  mosquito 
population.  So  there  is  an  increased  need  of 
such  studies.  Thus,  there  is  an  immediate 
requirement  of  time  to  assess  the  Aedes 
mosquito  population  breeding  sites  especially 
in different surroundings .Due to relative ease 
and  low  cost,  age  stratified  seroprevalence 
surveys have proven to be a useful tool in the 
surveillance  of  directly  transmitted  diseases 
(Egger, 2008). 
To reduce Dengue in our country the National 
Dengue  control  programmes  must  follow  all 
WHO  recommended  Dengue  control 
guidelines.  The  important  focused  points  in 
WHO  guidelines  are  the  public  health Asian J Agri Biol, 2013, 1(1):38-42. 
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education,  community  participation,  detection 
of  breeding  sites,  environmental  management 
by reactive insecticide fogging, geo referenced 
entomologic and clinical surveillance systems. 
The  local,  regional and  National  level  efforts 
are required to control this disease. Moreover, 
similar researches must be encouraged on large 
scales in different cities of Pakistan. 
 
CONCLUSION 
 
Thus,  by  seroprevalence  studies,  strictly 
adhering  to  WHO  guidelines  and 
recommendations, policies regarding screening, 
vector  control  activities  and  health  education 
awareness  campaigns,  along  with  community 
participation  should  be  established  to  reduce 
the morbidity and mortality rates.The resultant 
of  all  this  will  successfully  serve  as  an 
epidemiological  tool  in  early  warning  system 
for DF potential epidemics. 
Above all the final winning goal of fight will be 
the  discovery  of  DF  vaccine  or  specific 
antiviral agents. Otherwise dengue will grew up 
and  soon  take  an  epidemic  proportion  in  our 
country. 
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